Broken String rebrands to support genome programmes
Biotechnology company Broken String Biosciences has rebranded as the company repositions its strategic focus.
The company will now support early discovery programmes through to investigational new drug (IND)-enabling studies, moving away from its focus on being a specialist technology provider.
Broken String Biosciences, a company supporting the development of more effective genetic medicines, will expand capabilities of the INDUCE-seq platform – a complete in-house solution for genome-wide detection and quantification of DNA breaks.
With the redesigned website, the company says researchers can easily access a comprehensive resource library and gain a clear understanding of how the platform can be applied across gene editing workflows to maximise value in development pipelines.
The platform is scalable, cell-based and PCR-free, directly capturing and mapping individual induced and endogenous breaks at the point of formation within cells. It also delivers deeper understanding of editing kinetics, nuclease behaviours and cell repair pathways, enabling researchers to streamline preclinical decision-making and de-risk therapeutic development.
Ahead of the rebranding, Broken String Biosciences brought in Terry Pizzie as CEO in November 2025.
“Understanding DNA break activity in real cellular contexts is now a fundamental expectation for therapeutic programmes,” Pizzie said.
“Yet, too many programmes are still relying on approaches that are indirect, slow, or difficult to scale and that creates risk later in development. Our technology allows researchers to generate high-quality, genome-wide safety data in their own labs, early enough to influence decisions.
“This rebrand and website launch reflects that mission, providing customers with greater clarity about the role we play in helping teams move forward with confidence.”
